Email Us
Call Us
AUSTIN, Texas – September 21, 2021 – Altogen Labs today detailed its validated gastric cancer xenograft collection, comprising seven in-house validated models spanning the molecular subtypes that define modern gastric cancer development.
Gastric cancer is among the leading causes of cancer mortality worldwide and among the most molecularly heterogeneous. Programs targeting HER2, MET, FGFR2, and immune checkpoints all require models carrying the relevant alteration – and a compound tested against a model lacking its target will produce a null result that says nothing about the compound.
The Altogen Labs collection includes NCI-N87, widely used in HER2-directed antibody and antibody-drug conjugate development; MKN-45 and HS746T, established models for MET-driven disease; SNU5 and SNU-16, used in FGFR2-amplified and diffuse-type gastric cancer research; AGS; and SGC-7901.
Each model is validated in-house through tumor growth curves established and reproduced across multiple independent studies, and is available in subcutaneous, orthotopic, and metastatic configurations. Bioluminescent tracking is available for orthotopic studies where internal tumor burden cannot be assessed by caliper.
Study packages include tumor growth delay analysis, hematology, histopathology, biomarker screening, pharmacokinetic analysis, and molecular endpoint measurement by RT-PCR and automated capillary Western, delivered with complete raw data and statistical treatment.
About Altogen Labs
Altogen Labs is a preclinical CRO supporting drug development programs across oncology, pharmacology, toxicology, and translational research. The company has extensive experience with xenograft tumor models for preclinical efficacy studies and in vivo toxicology for safety evaluation, with a strong emphasis on high-quality, reproducible study execution and full client ownership of project-specific intellectual property. Altogen Labs works with pharmaceutical, biotechnology, and academic organizations worldwide to evaluate therapeutic candidates in validated in vivo models and generate data for efficacy, safety, PK/PD, pathology, and IND-supporting studies. The company provides integrated preclinical services from early-stage evaluation through advanced development.
Contact
Altogen Labs | 11200 Menchaca Rd, Bldg 2, Suite 203 | Austin, TX 78748 USA Tel: 512-433-6177 | Email: info@altogenlabs.com | Web: altogenlabs.com